Centers | ||
|
|
|
Presude Life Sciences | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
Presude Lifesciences is an integrated drug discovery and development services organization led by biopharma professionals with global experience. Read morePresude is a research driven company with expertise in medicinal chemistry, custom synthesis and... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Research collaboration and license agreementThe University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon... View all Yale to Partner with Gilead to Further Cancer ResearchYale and Gilead have entered into a multi-year research collaboration to develop new treatments against cancer. Gilead will provide $40million in funding for research and other infrastructure support for the initial four years. The agreement can... View all |
No EVENTS for listing |
No Job Posts |
